Efficacy of 125I seed implantation combined with intravenous chemotherapy in treatment of stage Ⅲ b and Ⅳ non-small cell lung cancer
10.13929/j.1672-8475.201705009
- VernacularTitle:125I粒子植入联合静脉化疗治疗Ⅲb期、Ⅳ期非小细胞肺癌的疗效
- Author:
Senlin CHU
1
;
Weifu LYU
;
Chunze ZHOU
;
Dong LU
;
Xingming ZHANG
;
Nan ZHU
Author Information
1. 安徽医科大学附属省立医院介入放射科
- Keywords:
Carcinoma,non-small cell lung;
125I particle;
Brachytherapy;
Combined chemotherapy
- From:
Chinese Journal of Interventional Imaging and Therapy
2017;14(10):592-596
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of implantation of radioactive iodine-125 (125I) seeds combined with chemotherapy in treatment of stage Ⅲb and Ⅳ non-small cell lung cancer (NSCLC).Methods Ninety patients with stage Ⅲb and Ⅳ NSCLC were divided into two groups.The combined group (n=43) received chemotherapy with TP (paclitaxe plus cispla tin) or GP (gemcitabine plus cisplatin) 3 days after 125I particles implantation,and the control group (n=47) only received TP or GP chemotherapy.The effective rate,1-year and 2-year survival rate,the median survival time were compared between the 2 groups.Results The total effective rates of the combined group and the control group of stage Ⅲ b NSCLC were 84.00％ and 48.28％,and the effective rates of stage Ⅵ NSCLC were 72.22％ and 33.33％ (both P＜0.05).The 1-year and 2-year survival rate of the combined group and control group of stage Ⅲb NSCLC were 67.80％,36.00％ and 37.90％,13.83％,respectively (both P＜0.05).The median survival time was 15.7 months and 8.6 months.However,the survival rates of the combined group and the control group of stage Ⅳ NSCLC were 44.44％,16.70％ and 22.22％,11.10％,respectively,while the difference was not statistically significant (P＞0.05).The median survival time was 8.9 and 6.0 months.Conclusion The implantation of radioactive 125I seeds combined with chemotherapy can obtain a significant efficacy in the treatment of stage Ⅲb and stage Ⅳ NSCLC.For patients with stage Ⅲb NSCLC,combined therapy can improve the survival rate.
